Do low EPA, total omega-3, and DPA reduce the substrate for inflammation-resolving mediators?

Long-chain omega-3 fatty acids—specifically eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA)—are critical structural components of cell membranes that serve as the direct precursor pool for resolving active inflammatory states.

Mechanistic pathways of resolution

• Enzymatic conversion: During an inflammatory response, phospholipases liberate EPA, DPA, and DHA from cell membranes. These are converted via cyclooxygenase (COX) and lipoxygenase (LOX) pathways into lipid mediators known as specialized pro-resolving mediators (SPMs), including E-series resolvins, protectins, maresins, and DPA-derived SPMs.
• Substrate competition: When tissue levels of total omega-3s are low, the synthesis of critical SPM precursors (such as the EPA-derived intermediate 18-HEPE) is restricted. This lack of substrate shifts cellular machinery toward producing pro-inflammatory eicosanoids derived from arachidonic acid.

Cellular and systemic implications

• Immune cell reprogramming: SPMs operate at highly potent nanomolar to picomolar concentrations. They bind to specific G-protein coupled receptors on immune cells to actively halt further neutrophil recruitment, shorten neutrophil lifespan, and promote non-phlogistic macrophage phagocytosis of apoptotic cells.
• Systemic biomarker reduction: Active resolution of inflammation driven by SPMs suppresses upstream pro-inflammatory cytokines, specifically IL-6, IL-1beta, and TNF-alpha. This suppression subsequently reduces the hepatic synthesis of systemic inflammatory markers, notably high-sensitivity C-reactive protein (hs-CRP).

Bottom line

• Deficient membrane levels of EPA, DPA, and total omega-3 fatty acids limit the substrate available for enzymatic SPM synthesis, which impairs the active mechanisms required to terminate inflammation and downregulate systemic inflammatory markers like hs-CRP.